bioAffinity Technologies, Inc. Deferred Tax Assets, in Process Research and Development
bioAffinity Technologies, Inc. (BIAF) had Deferred Tax Assets, in Process Research and Development of $817.59 thousand as of 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2026-03-16
- 2025-12-31: Deferred Tax Assets, in Process Research and Development $817.59K.
- 2024-12-31: Deferred Tax Assets, in Process Research and Development $662.86K.
- 2023-12-31: Deferred Tax Assets, in Process Research and Development $525.46K.
- 2022-12-31: Deferred Tax Assets, in Process Research and Development $260.56K.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2025-12-31 | $817.59K 10-K · filed 2026-03-16 |
| 2024-12-31 | $662.86K 10-K · filed 2026-03-16 |
| 2023-12-31 | $525.46K 10-K · filed 2025-03-31 |
| 2022-12-31 | $260.56K 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |